Table 1. Objective Response Rate Subgroup Analyses

 Number of PatientsObjective Response (CR + PR) n(%)
ITT13226 (19.7)
Number of Prior chemotherapies for metastatic disease  
16714 (20.9)
26411 (17.2)
311 (100.0)
Taxane use in the metastatic setting  
Yes9119 (20.9)
No417 (17.1)
Capecitabine use in the metastatic setting  
Yes7616 (21.1)
No5610 (17.9)
Number of prior endocrine therapies for metastatic disease  
0173 (17.6)
1489 (18.8)
2 or more6714 (20.9)
Fulvestrant use in the metastatic setting  
Yes6715 (22.4)
No6511 (16.9)
Number of metastatic sites  
1194 (21.1)
24610 (21.7)
3 or more6712 (17.9)
Liver metastases  
Yes9320 (21.5)
No396 (15.4)
  • References: 1. Dickler, M. et al. American Society of Clinical Oncology (ASCO), abstract #510 (2016).